Genetically engineered cell factories produce glycoengineered vaccines that target antigen-presenting cells and reduce antigen-specific T-cell reactivity.
Mathiesen CBK, Carlsson MC, Brand S, Möller SR, Idorn M, Thor Straten P, Pedersen AE, Dabelsteen S, Halim A, Würtzen PA, Brimnes J, Ipsen H, Petersen BL, Wandall HH.
Mathiesen CBK, et al. Among authors: pedersen ae.
J Allergy Clin Immunol. 2018 Dec;142(6):1983-1987. doi: 10.1016/j.jaci.2018.07.030. Epub 2018 Aug 17.
J Allergy Clin Immunol. 2018.
PMID: 30125661
No abstract available.